Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

Non-Hodgkin’s lymphoma (NHL) is the sixth most common cause of cancer deaths in the U.S. Most NHLs initially respond well to chemotherapy, but relapse is common and treatment is often limited due to the toxicity of chemotherapeutic agents. Pegylated-liposomal doxorubicin (PLD, Ben Venue Laboratories...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: O’Donnell, Robert T., Martin, Shiloh M., Ma, Yunpeng, Zamboni, William C., Tuscano, Joseph M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2009
Soggetti:
Preclinical Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2850518/
https://ncbi.nlm.nih.gov/pubmed/19306119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-009-9243-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi